AZD 0095
Alternative Names: AZD-0095Latest Information Update: 28 Apr 2023
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Monocarboxylic acid transporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
- 09 Jun 2022 Pharmacodynamics data from preclinical studies in Cancer presented at the 27th Congress of the European Haematology Association (EHA-2022)
- 29 Mar 2019 Pharmacodynamics data from preclinical studies in Cancer presented at the 110thAnnual Meeting of the American Association for Cancer Research (AACR-2019)